A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia-Reference-Cited by-同舟云学术

A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia

Published:2022-11-10 Issue:1 Volume:42 Page:26-34
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Burke Alan^ORCID,Borot Florence,Du Xing,Churchill Michael,Ding Jian,Grass Albert Mridul,DeSouza Philip^ORCID,Ali Abdullah Mahmood^ORCID,Mukherjee Siddhartha

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

https://www.nature.com/articles/s41388-022-02532-2.pdf

Reference18 articles.

1. Brinkmann U, Kontermann RE. Bispecific antibodies. Science. 2021;372:916–7.

2. Krah S, Sellmann C, Rhiel L, Schroter C, Dickgiesser S, Beck J, et al. Engineering bispecific antibodies with defined chain pairing. N. Biotechnol. 2017;39:167–73.

3. Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol Immunol. 2020;17:451–61.

4. Golay J, Choblet S, Iwaszkiewicz J, Cerutti P, Ozil A, Loisel S, et al. Design and validation of a novel generic platform for the production of tetravalent IgG1-like bispecific antibodies. J Immunol. 2016;196:3199–211.

5. Ha JH, Kim JE, Kim YS. Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins. Front Immunol. 2016;7:394.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design and engineering of bispecific antibodies: insights and practical considerations;Frontiers in Bioengineering and Biotechnology;2024-01-25